Arca
Skip to content
Tools
Tools

TNFRSF17: Tumor necrosis factor receptor superfamily member 17

Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL.

  • Drugs that act on it: 5
  • Approved: 5
  • In phases 1 to 3: 0
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on TNFRSF17, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 2
  • Antibody-drug conjugate 1
  • Other 2

Approved5

  • Teclistamab
  • Elranatamab
  • Belantamab mafodotin
  • Ciltacabtagene autoleucel
  • Idecabtagene vicleucel

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        • Dispatch Biotherapeutics120%

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Tumor necrosis factor receptor superfamily member 17 binding agent.
        TeclistamabBoxed warningApprovedJohnson & JohnsonAntibodyBinding agent66
        ElranatamabBoxed warningApprovedPfizerAntibodyBinding agent50
        Belantamab mafodotinWithdrawn Boxed warningApprovedGSKAntibody-drug conjugateBinding agent47
        Ciltacabtagene autoleucelBoxed warningApprovedJohnson & JohnsonGeneBinding agent23
        Idecabtagene vicleucelBoxed warningApprovedDispatch BiotherapeuticsGeneBinding agent19

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 40 in all, from ClinicalTrials.gov.
        A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaElranatamab—Not yet recruitingPfizerNov 9, 2026
        Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaElranatamabPhase 2Not yet recruitingPETHEMA FoundationOct 28, 2026
        RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of ElranatamabElranatamab—Not yet recruitingThe Royal Wolverhampton Hospitals NHS TrustOct 23, 2026
        Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaTeclistamabPhase 2 / Phase 3Not yet recruitingAlliance for Clinical Trials in OncologyOct 22, 2026
        A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsElranatamabPhase 4Not yet recruitingPfizerOct 19, 2026
        Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple MyelomaIdecabtagene vicleucelNot applicableNot yet recruitingCentre Henri BecquerelOct 1, 2026
        The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.Belantamab mafodotinPhase 2Not yet recruitingMedical Association for the Study of Cancer Biology and TreatmentSep 28, 2026
        Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Belantamab mafodotinPhase 1Not yet recruitingCanadian Myeloma Research GroupSep 21, 2026
        Teclistamab In Waldenstrom's MacroglobulinemiaTeclistamabPhase 2Not yet recruitingMassachusetts General HospitalAug 28, 2026
        Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple MyelomaElranatamabPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaAug 27, 2026
        A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia AElranatamabNot applicableNot yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaAug 26, 2026
        Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.TeclistamabPhase 2Not yet recruitingOdense University HospitalAug 11, 2026
        Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Belantamab mafodotinPhase 2Not yet recruitingPolish Myeloma ConsortiumAug 6, 2026
        A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseTeclistamabPhase 3Not yet recruitingPolish Myeloma ConsortiumJul 31, 2026
        A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaTeclistamabPhase 3RecruitingAbbVieJul 27, 2026
        Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaCiltacabtagene autoleucelPhase 1RecruitingWeill Medical College of Cornell UniversityJul 24, 2026
        TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Belantamab mafodotinPhase 1Not yet recruitingMontefiore Medical CenterJul 22, 2026
        Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney TransplantationTeclistamabEarly phase 1Not yet recruitingWest China HospitalJul 15, 2026
        Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%TeclistamabPhase 4Not yet recruitingWest China HospitalJul 8, 2026
        GMMG-HD11/DSMM XXI/64007957MMY3010TeclistamabPhase 3Not yet recruitingUniversity of Heidelberg Medical CenterJun 26, 2026
        Delayed Toxicities Post-CAR-TCiltacabtagene autoleucel—RecruitingIcahn School of Medicine at Mount SinaiJun 24, 2026
        HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIVElranatamabPhase 1RecruitingUniversity of Illinois ChicagoJun 15, 2026
        A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomaElranatamabPhase 2RecruitingSCRI Development Innovations, LLCJun 10, 2026
        Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple MyelomaBelantamab mafodotin—Not yet recruitingPETHEMA FoundationJun 9, 2026
        A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple MyelomaBelantamab mafodotinPhase 1 / Phase 2Not yet recruitingCentre Hospitalier Universitaire de Saint EtienneMay 29, 2026
        Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaBelantamab mafodotinPhase 2Not yet recruitingGlaxoSmithKlineMay 29, 2026
        A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic ImpairmentBelantamab mafodotinPhase 1Not yet recruitingGlaxoSmithKlineMay 27, 2026
        BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple MyelomaCiltacabtagene autoleucelNot applicableRecruitingUniversitätsklinikum Hamburg-EppendorfMay 4, 2026
        A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal CancersIdecabtagene vicleucelPhase 1RecruitingDispatch BiotherapeuticsApr 22, 2026
        Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple MyelomaIdecabtagene vicleucelPhase 1 / Phase 2RecruitingMinsk Scientific-Practical Center for Surgery, Transplantation and HematologyMar 17, 2026
        Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple MyelomaIdecabtagene vicleucelPhase 1RecruitingHadassah Medical OrganizationJan 12, 2026
        Selinexor Maintenance Post CAR-T Cell Therapy for Multiple MyelomaCiltacabtagene autoleucelPhase 1RecruitingWashington University School of MedicineSep 30, 2025
        Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)Ciltacabtagene autoleucelPhase 1RecruitingWashington University School of MedicineSep 30, 2025
        A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelCiltacabtagene autoleucelPhase 2RecruitingJanssen Research & Development, LLCSep 2, 2025
        Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaCiltacabtagene autoleucelPhase 1RecruitingMedical College of WisconsinJul 30, 2025
        A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligibleIdecabtagene vicleucelNot applicableNot yet recruitingXuzhou Medical UniversityJul 17, 2025
        CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?Idecabtagene vicleucelPhase 2Not yet recruitingXuzhou Medical UniversityJul 17, 2025
        Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed MyelomaCiltacabtagene autoleucelPhase 2RecruitingH. Lee Moffitt Cancer Center and Research InstituteApr 27, 2025
        Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple MyelomaIdecabtagene vicleucelPhase 1Not yet recruitingXuzhou Medical UniversityApr 6, 2025
        The Norwegian Immunotherapy in Multiple Myeloma StudyIdecabtagene vicleucel—RecruitingSt. Olavs HospitalMar 3, 2025

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Plasma cell myeloma0.68
        • Neoplasm0.53
        • Gastric carcinoma0.43
        • Neurodegenerative disease0.39
        • Exocrine pancreatic carcinoma0.37
        • Breast carcinoma0.29
        • Esophageal squamous cell carcinoma0.29

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4523587, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q02223, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.